News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,743 Results
Type
Article (13743)
Company Profile (255)
Press Release (242745)
Section
Business (79178)
Career Advice (147)
Deals (13168)
Drug Delivery (28)
Drug Development (50178)
Employer Resources (31)
FDA (5639)
Job Trends (5103)
News (143658)
Policy (10011)
Tag
Academia (901)
Africa (145)
Allergies (30)
Alliances (21406)
Alzheimer's disease (688)
Antibody-drug conjugate (ADC) (32)
Approvals (5612)
Arizona (38)
Artificial intelligence (35)
Asia (16659)
Australia (2787)
Bankruptcy (96)
Best Places to Work (4371)
Biotechnology (214)
C2C Services and Suppliers (10603)
California (1309)
Canada (520)
Cancer (340)
Career advice (128)
CAR-T (34)
Cell therapy (101)
China (97)
Clinical research (39151)
Collaboration (104)
Colorado (43)
Compensation (43)
Connecticut (45)
COVID-19 (982)
Cystic fibrosis (61)
Data (302)
Diabetes (42)
Diagnostics (1161)
Earnings (28366)
Employer resources (29)
Europe (35759)
Events (45871)
Executive appointments (105)
FDA (5781)
Florida (134)
Funding (110)
Gene therapy (86)
GLP-1 (265)
Government (1054)
Healthcare (6510)
Hotbed/Location (184111)
Illinois (83)
Indiana (45)
Infectious disease (995)
Inflammatory bowel disease (80)
IPO (7139)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1369)
Lung cancer (76)
Manufacturing (36)
Maryland (200)
Massachusetts (1053)
Medical device (2517)
Medtech (2518)
Mergers & acquisitions (6044)
Metabolic disorders (143)
Michigan (38)
Minnesota (66)
Neuroscience (812)
New Jersey (349)
New York (419)
NextGen Class of 2024 (1977)
Non-profit (837)
North Carolina (332)
Northern California (573)
Obesity (82)
Ohio (64)
Opinion (87)
Parkinson's disease (39)
Patents (36)
Pennsylvania (289)
People (24732)
Pharmaceutical (41)
Phase I (13730)
Phase II (18205)
Phase III (11583)
Pipeline (85)
Postmarket research (845)
Preclinical (5779)
Press Release (30)
Radiopharmaceuticals (199)
Rare diseases (113)
Real estate (1406)
Regulatory (8055)
Research institute (928)
South America (206)
Southern California (542)
Startups (1963)
Texas (121)
United States (4944)
Vaccines (137)
Washington State (157)
Weight loss (60)
Date
Last 7 days (334)
Last 30 days (1426)
Last 365 days (21198)
2024 (15471)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
256,743 Results for "swanbio therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer
SwanBio Therapeutics announced the addition of two industry veterans to the company’s leadership team: John Tsai, MD as executive chair, and Christopher “Topher” Brooke as chief operating officer.
October 16, 2023
·
3 min read
Drug Development
SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy
SwanBio Therapeutics today announced it has begun the second dose-escalation cohort of its first interventional clinical study, PROPEL.
October 4, 2023
·
4 min read
Pharm Country
SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, has conducted a healthcare resource use study confirming the substantial burden and economic impact of AMN on both men and women.
May 10, 2023
·
4 min read
Drug Development
SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
SwanBio Therapeutics today announced the initiation of its PROPEL clinical trial.
December 15, 2022
·
3 min read
Pharm Country
SwanBio Unveils Research in Next Generation CNS Capsids at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, presented preliminary data from primate studies of AAV capsids that outperform the commonly used AAV9 capsid.
May 18, 2023
·
4 min read
Drug Development
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy
SwanBio Therapeutics to Present Preclinical Data on Lead Candidate at American Society of Gene & Cell Therapy 2022 Annual Meeting in Washington, DC May 16-19.
April 19, 2022
·
4 min read
Pharm Country
SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions
SwanBio Therapeutics, a gene therapy company advancing adeno-associated virus -based therapies for the treatment of devastating, inherited neurological conditions, announced the completion of a $56 million Series B financing round, led by founding investors Syncona Limited and Mass General Brigham Ventures.
May 18, 2022
·
4 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Pharm Country
SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments
SwanBio Therapeutics, a gene therapy company advancing AAV-based therapies for the treatment of devastating, inherited neurological conditions, today presented details about the company’s ongoing natural history study of adrenomyeloneuropathy (AMN) at the 8th Congress of the European Academy of Neurology (EAN) in Vienna.
June 27, 2022
·
4 min read
1 of 25,675
Next